Revenue (Tables)

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table presents the approximate percentage of our net sales by market group:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2023	2022	2023	2022
Biologics	40 %	41 %	37 %	42 %
Generics	19 %	18 %	20 %	18 %
Pharma	22 %	24 %	24 %	24 %
Contract-Manufactured Products	19 %	17 %	19 %	16 %
	100 %	100 %	100 %	100 %

The following table presents the approximate percentage of our net sales by product category:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2023	2022	2023	2022
High-Value Product Components	50 %	54 %	50 %	56 %
High-Value Product Delivery Devices	11 %	6 %	10 %	5 %
Standard Packaging	20 %	23 %	21 %	23 %
Contract-Manufactured Products	19 %	17 %	19 %	16 %
	100 %	100 %	100 %	100 %

Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023.

The following table presents the approximate percentage of our net sales by geographic location:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2023	2022	2023	2022
Americas	46 %	53 %	45 %	48 %
Europe, Middle East, Africa	46 %	38 %	46 %	43 %
Asia Pacific	8 %	9 %	9 %	9 %
	100 %	100 %	100 %	100 %

Schedule of Change in Contract with Customer, Asset and Liability

The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:

	($ in millions)
Contract assets, December 31, 2022	$	16.3
Contract assets, September 30, 2023	19.9
Change in contract assets - increase (decrease)	$	3.6
Deferred income, December 31, 2022	$	(68.2)
Deferred income, September 30, 2023	(50.0)
Change in deferred income - decrease (increase)	$	18.2